Biocryst Pharmaceuticals (BCRX) Gross Margin (2010 - 2026)
Biocryst Pharmaceuticals' (BCRX) quarterly Gross Margin came in at 96.56% in Q1 2026, down 30.0% YoY from 137.95% in Q1 2025, and up 107.76% on a QoQ basis from 1244.92% in Q4 2025.
Biocryst Pharmaceuticals (BCRX) Gross Margin (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has 16 years of Gross Margin data on file, last reported at 96.56% in Q1 2026.
- Quarterly Gross Margin fell 30.0% year-over-year to 96.56% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 95.86% (down 105.0% YoY) and the FY2025 annual result came in at 97.82%, up 54.0% from the prior year.
- Gross Margin rose to 96.56% in Q1 2026, from 1244.92% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 99.62% in Q2 2022 to a low of 1244.92% in Q4 2025.
- A 5-year average of 18.9% and a median of 98.33% in 2023 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2022 — Gross Margin jumped 3060 bps — and 2025, when it slumped 134028 bps.
- Tracing BCRX's Gross Margin over 5 years: stood at 97.0% in 2022, then climbed by 1 bps to 98.33% in 2023, then retreated by 3 bps to 95.37% in 2024, then slumped by 1405 bps to 1244.92% in 2025, then surged by 108 bps to 96.56% in 2026.
- The last three Gross Margin figures came in at 96.56% (Q1 2026), 1244.92% (Q4 2025), and 98.63% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 51.98% |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 42.63% |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 66.66% |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 87.30% |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 38.77% |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 97.58% |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 58.33% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Biocryst Pharmaceuticals | 2.46 Bn | 2.11 Bn | 214.41 Mn | 98.24% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 98.24% |
| Mar 31, 2026 | 96.56% |
| Dec 31, 2025 | -1,244.92% |
| Sep 30, 2025 | 98.63% |
| Jun 30, 2025 | 98.29% |
| Mar 31, 2025 | 96.86% |
| Dec 31, 2024 | 95.37% |
| Sep 30, 2024 | 97.26% |
| Jun 30, 2024 | 98.45% |
| Mar 31, 2024 | 98.64% |
| Dec 31, 2023 | 98.33% |
| Sep 30, 2023 | 98.73% |
| Jun 30, 2023 | 98.92% |
| Mar 31, 2023 | 98.65% |
| Dec 31, 2022 | 97.00% |
| Sep 30, 2022 | 95.33% |
| Jun 30, 2022 | 99.62% |
| Mar 31, 2022 | 99.53% |
| Dec 31, 2021 | 99.11% |
| Sep 30, 2021 | 98.56% |